1-10 of 10
Jesse McGreivy
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Results from the Randomized, Multicenter, Global Phase 3 BOREAS Study: Navtemadlin Versus Best Available Therapy in JAK Inhibitor Relapsed / Refractory Myelofibrosis

John O. Mascarenhas, Viola Maria Popov, Sanjay Mohan, Zübeyde Nur Özkurt, Jean-Jacques Kiladjian, Haifa Kathrin Al-Ali, Andrew Perkins, Zhuying Huang, Hope Qamoos, Jesse McGreivy, Wayne Rothbaum, Srdan Verstovsek, Maciej Kaźmierczak
Journal: Blood
Blood (2024) 144 (Supplement 1): 1000.
https://doi.org/10.1182/blood-2024-201642
Published: 2024
Journal Articles

Disease-Modifying Activity of Navtemadlin Correlates with Clinical Responses in a Randomized, Multicenter, Global Phase 3 Study (BOREAS) in JAK-Inhibitor Relapsed/Refractory Myelofibrosis

John O. Mascarenhas, Prithviraj Bose, Hsin-An Hou, Wojciech Homenda, David Ross, Sanjay R Mohan, Jean-Jacques Kiladjian, Haifa Kathrin Al-Ali, Andrew Perkins, Yulia Khalina, Tracy Clevenger, Zhuying Huang, Jesse McGreivy, Wayne Rothbaum, Srdan Verstovsek, Alessandro M. Vannucchi
Journal: Blood
Blood (2024) 144 (Supplement 1): 483.
https://doi.org/10.1182/blood-2024-205937
Published: 2024
Journal Articles

A Phase (Ph) 2 Study of TL-895, a Highly Selective, Novel Covalent BTK Inhibitor (BTKi), in Patients (pts) with Treatment-Naïve (TN) and Relapsed/Refractory (R/R) BTKi-Naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

John C. Byrd, Dariusz Woszczyk, Arpad Illes, Wojciech Jurczak, Dominik Chraniuk, Krzysztof Giannopoulos, Nataliia Mikhailova, Peter Illconzai, Seema A Bhat, Nataliya Romanyuk, Ganna Usenko, Olha Kuchkova, Jason Chandler, Elizabeth Bilotti, Annalise Shen, Jean Cheung, Srdan Verstovsek, Jesse McGreivy, Wayne Rothbaum, Maciej Kaźmierczak
Journal: Blood
Blood (2023) 142 (Supplement 1): 4634.
https://doi.org/10.1182/blood-2023-186517
Published: 2023
Journal Articles

Potential Disease-Modifying Activity of Navtemadlin (KRT-232), a First-in-Class MDM2 Inhibitor, Correlates with Clinical Benefits in Relapsed/Refractory Myelofibrosis (MF)

Pankit Vachani, Andrzej Lange, Regina Garcia Delgado, Haifa Kathrin Al-Ali, Jesus Maria Hernández-Rivas, Jean-Jacques Kiladjian, Alessandro Vannucchi, Andrew Charles Perkins, Venu Valmeekam, Cecile Marie Krejsa, Anne Uyei, Jesse McGreivy, Wayne P. Rothbaum, John Mascarenhas, Srdan Verstovsek
Journal: Blood
Blood (2021) 138 (Supplement 1): 3581.
https://doi.org/10.1182/blood-2021-147543
Published: 2021
Journal Articles

A Randomized, Open-Label, Multicenter, Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of KRT-232 Compared with Ruxolitinib in Patients with Phlebotomy-Dependent Polycythemia Vera

Jason Gotlib, MD MS, Nashat Gabrail, MD, Casey L. O'Connell, MD, Regina Garcia-Delgado, MD, Timothy Sbardellati, Wayne M. Rothbaum, Jesse McGreivy, Claire N Harrison, Professor, Jean-Jacques Kiladjian, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4168.
https://doi.org/10.1182/blood-2019-123546
Published: 2019
Journal Articles

An Open-Label, Phase 2 Study of KRT-232, a First-in-Class, Oral Small Molecule Inhibitor of MDM2, for the Treatment of Patients with Myelofibrosis (MF) Who Have Previously Received Treatment with a JAK Inhibitor

Regina Garcia-Delgado, MD, Donal P. McLornan, MB, BCh (Hons), MRCP, PhD FRCPath, László Rejtő, Eric Jourdan, MD, Haifa Kathrin Al-Ali, MD, Andrzej Pluta, MD, Marek Hus, MD PhD, Joanne Ewing, PhDBMBS BSc FRPATH, Irum Khan, MD, Holger Hebart, Philipp J. Jost, MD, Sebastian Grosicki, MD PhD, Wayne M. Rothbaum, Jesse McGreivy, Srdan Verstovsek, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2945.
https://doi.org/10.1182/blood-2019-123836
Published: 2019
Journal Articles

Updated Efficacy Including Genetic and Clinical Subgroup Analysis and Overall Safety in the Phase 3 RESONATE TM Trial of Ibrutinib Versus Ofatumumab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Jennifer R. Brown, MD PhD, Peter Hillmen, MB, ChB, PhD, Susan O'Brien, MD, Jaqueline C. Barrientos, MD, Nishitha Reddy, MBBS, MScl, Steven Coutre, MD, Constantine Tam, MD, Stephen Mulligan, MBBS, MD FRACP, FRCPA, Ulrich Jaeger, MD, Paul M. Barr, MD, Richard R. Furman, MD, Thomas J. Kipps, MD, Florence Cymbalista, MD, Patrick Thornton, MD, Federico Caligaris-Cappio, MD, Julio Delgado, MD, Marco Montillo, MD, Sven DeVos, MD, Carol Moreno, MD, John Pagel, MD PhD, Jan A. Burger, MD PhD, Devon Chung, BS, Jennifer Lin, MA, MS, Linda Gau, MS, Betty Chang, PhD, Jesse McGreivy, MD, Danelle F. James, MD MAS, John C. Byrd, MD
Journal: Blood
Blood (2014) 124 (21): 3331.
https://doi.org/10.1182/blood.V124.21.3331.3331
Published: 2014
Journal Articles

The Bruton's Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Is Active and Tolerated in Relapsed Follicular Lymphoma

Nathan H Fowler, MD, Ranjana H Advani, MD, Jeff Sharman, MD, Sonali M. Smith, MD, Jesse McGreivy, MD, Lori Kunkel, MD, Vina Troung, Cathy Zhou, Thomas E. Boyd, MD
Journal: Blood
Blood (2012) 120 (21): 156.
https://doi.org/10.1182/blood.V120.21.156.156
Published: 2012
Journal Articles

The Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), Has Preferential Activity in the ABC Subtype of Relapsed/Refractory De Novo Diffuse Large B-Cell Lymphoma (DLBCL): Interim Results of a Multicenter, Open-Label, Phase 2 Study

Wyndham H. Wilson, MD, PhD, John F. Gerecitano, MD, PhD, Andre Goy, MD, Sven de Vos, MD, PhD, Vaishalee P. Kenkre, MD, Paul M. Barr, MD, Kristie A. Blum, MD, Andrei R. Shustov, MD, Ranjana H. Advani, MD, Jason Lih, PhD, Mickey Williams, PhD, Roland Schmitz, PhD, Yandan Yang, PhD, Stefania Pittaluga, MD, PhD, George Wright, PhD, Lori A. Kunkel, MD, Jesse McGreivy, MD, Sriram Balasubramanian, PhD, Mei Cheng, PhD, Davina Moussa, Joseph J. Buggy, PhD, Louis M. Staudt, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 686.
https://doi.org/10.1182/blood.V120.21.686.686
Published: 2012
Journal Articles

Interim Results of an International, Multicenter, Phase 2 Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Relapsed or Refractory Mantle Cell Lymphoma (MCL): Durable Efficacy and Tolerability with Longer Follow-up

Michael Wang, M.D., Simon A. Rule, MD, Peter Martin, MD, Andre Goy, MD, Rebecca Auer, MD, Brad S. Kahl, M.D., Wojciech Jurczak, Ranjana H. Advani, MD, Jorge Enrique E Romaguera, MD, Jesse McGreivy, MD, Fong Clow, ScD, Michelle Stevens-Brogan, Lori Kunkel, MD, Kristie A. Blum, MD
Journal: Blood
Blood (2012) 120 (21): 904.
https://doi.org/10.1182/blood.V120.21.904.904
Published: 2012